Browse Studies — Arctuva

Phase 1

A Phase 1b, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Subretinal Dose of ASP2020 in Participants With Macular Dystrophies With a Stargardt-type Clinical Presentation

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the …

Stargardt DiseaseStargardt Macular DystrophyStargardt-like Macular Dystrophy

Estimated

~$10 – $7,500

Astellas Institute for Regenerative MedicineNCT07734064

An Observational Study of Natural Disease Progression in Participants With Macular Dystrophies Expressing a Stargardt-type Clinical Presentation

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the …

Stargardt DiseaseStargardt Macular DystrophyStargardt-like Macular Dystrophy

Estimated

~$10 – $1,050

Astellas Pharma Global Development, Inc.NCT07425574

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with …

Retinitis PigmentosaStargardt Macular DystrophyStargardt Disease+3 more

Estimated

~$10 – $1,050

Ray Therapeutics, Inc.NCT07502664

Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with …

Retinitis PigmentosaChoroideremiaStargardt Macular Dystrophy+4 more

Estimated

~$10 – $1,050

Ray Therapeutics, Inc.NCT06375239

Phase 1

A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjec…

Stargardt DiseaseStargardt Macular DegenerationStargardt Macular Dystrophy

Estimated

~$10 – $7,500

Splice BioNCT06942572